Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
45 hedge funds and large institutions have $169M invested in Neon Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 18 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
10% more funds holding
Funds holding: 41 → 45 (+4)
28% less capital invested
Capital invested by funds: $233M → $169M (-$64.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Partner Investment Management
San Francisco,
California
|
+$9.2M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$7.19M |
| 3 |
PI
Pharmstandard International
Luxembourg
|
+$6.52M |
| 4 |
BlackRock
New York
|
+$3.05M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.55M |
| 2 |
Millennium Management
New York
|
-$2.02M |
| 3 |
PC
PointState Capital
New York
|
-$1.89M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.57M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.47M |
NTGN Hedge Fund Activity: Q3 2018 in Review
45 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q3 2018, worth a combined $169M — down 28% from $233M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NTGN positions and 18 closed out — a net gain of 4 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Partner Investment Management, adding an estimated $9.2M. The largest seller was Fidelity Investments, cutting an estimated $2.55M.
- 45 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q3 2018, up from 41 in Q2 2018.
- Funds reported $169M of Neon Therapeutics, Inc. Common Stock stock for Q3 2018, down 28% quarter-over-quarter.
- 22 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q3 2018 and 18 closed out, a net change of +4 holders.
- The largest Neon Therapeutics, Inc. Common Stock buyer in Q3 2018 was Partner Investment Management, an estimated $9.2M added.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q3 2018 was Fidelity Investments, an estimated $2.55M sold.
Based on aggregated 13F filings for Q3 2018.